logo
Melanoma can be deadly: What to know about the disease that killed Kelly Clarkson's ex

Melanoma can be deadly: What to know about the disease that killed Kelly Clarkson's ex

Fox News19 hours ago
Days after Kelly Clarkson's ex-husband, Brandon Blackstock, passed away at the age of 48, the cause of his death was revealed.
On August 11, it was reported that the talent manager died after a private battle with melanoma, a form of skin cancer.
"Brandon Blackstock passed away peacefully at his home in Butte, Montana on August 7 under hospice care surrounded by his family," Silver Bow County Coroner Dan Hollis told Fox News Digital.
"It is with great sadness that we share the news that Brandon Blackstock has passed away. Brandon bravely battled cancer for more than three years. He passed away peacefully and was surrounded by family. We thank you for your thoughts and prayers and ask everyone to respect the family's privacy during this very difficult time."
The singer, who was married to Blackstock for seven years before their divorce in 2022, reportedly "remained protective" of her ex as he battled cancer for three years.
Skin cancer is the most common type of cancer in the U.S. — with one in five Americans developing the disease by the age of 70.
Melanoma is the deadliest form of skin cancer, expected to take the lives of more than 8,400 people in the U.S. this year, according to the American Cancer Society.
"Melanoma has a significantly higher chance of spreading than basal cell and squamous cell carcinomas, the most common types of skin cancer," said Marcus Monroe, MD, surgeon and investigator with the Huntsman Cancer Institute and associate professor at the University of Utah School of Medicine, previously told Fox News Digital.
The chances of melanoma spreading to other locations increases with each stage of cancer.
"For the earliest stage, this risk is estimated at less than 5%, increasing for patients with stage 2 disease to a wider range, from 5% at the low end up to 40% to 50% for the most advanced stage 2 patients," said Monroe.
In stage 3 patients (those with regional spread either via in-transit metastases or to adjacent lymph nodes), up to 30% to 40% will develop distant metastases, with a 16% to 17% risk of brain metastases, the doctor added.
Melanoma is the deadliest form of skin cancer, expected to take the lives of more than 8,400 people in the U.S. this year.
The brain and lungs are the most common sites of metastasis for melanoma, experts confirmed.
If the patient has lesions that are deep in the skin or involve the lymph nodes, the chance of melanoma spreading is higher — anywhere from 20% to 70%, according to Jose Lutzky, MD, director of cutaneous oncology services at the Sylvester Comprehensive Cancer Center in South Florida.
Metastatic melanoma was once considered mostly treatment-resistant because it did not respond to traditional chemotherapy and radiation, noted Dr. Joshua Strauss from Advanced Care Oncology and Hematology Associates of the Atlantic Medical Group in Morristown, New Jersey.
"Nowadays, using targeted therapies and immunotherapy survival has been dramatically improved, and there is a possibility of long-term remission with treatment," Strauss previously told Fox News Digital.
Lutzky noted that melanoma is almost always curable by surgical removal when it's detected early.
"Because of advances in the treatment of melanoma over the last 10 to 15 years, even very advanced melanoma can be cured in up to 50% of cases with modern immunotherapy treatment," he told Fox News Digital.
"More recently, cell therapy has been approved to treat those advanced melanomas that do not respond to immunotherapy."
To prevent melanoma, it's important to reduce exposure to ultraviolet radiation, especially in people with lightly pigmented skin, Strauss advised.
"Sunscreen and sun-protective clothing are critical," he said.
The American Academy of Dermatology recommends applying water-resistant sunscreen with broad-spectrum protection against UVA and UVB rays, and SPF 30 or higher, before sun exposure.
"Indoor tanning bed use should be avoided because it is known to be associated with increased melanoma risk," Strauss added.
High-risk individuals should also have yearly skin checks with a dermatologist.
"This includes individuals with a personal history of skin cancer, family history of melanoma, people who take medications that suppress the immune system, and people who are highly sun-sensitive, such as those with red or blond hair, light skin pigmentation, significant freckling and light eye color," the oncologist said.
For more Health articles, visit www.foxnews.com/health
Strauss uses the acronym ABCDE to differentiate between a normal mole and a melanoma.
"Moles with Asymmetry, irregular Borders, multiple Colors, Diameter larger than a pencil eraser, and Evolving or changing characteristics require further evaluation," he said.
Fox News' Christina Dugan Ramirez contributed reporting.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Yahoo

time5 minutes ago

  • Yahoo

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (''2510') anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ('Instil') (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer In July, announced the Investigational New Drug (IND) application for '2510 was cleared by the U.S. FDA In July, ImmuneOnco, Instil's collaborator, announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of '2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC's 2025 World Conference on Lung Cancer (September 6th-9th, 2025), which will provide updated results from additional patients with relapsed/refractory squamous-NSCLC treated with '2510 as monotherapy Second Quarter 2025 Financial and Operating Results: As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024, consisting of $8.8 million in cash and cash equivalents, $1.8 million in restricted cash, and $104.5 million in marketable securities. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of June 30, 2025 will enable it to fund its operating plan beyond 2026. In-process research and development expenses were $10.0 million for both the three and six months ended June 30, 2025, compared to nil for both the three and six months ended June 30, 2024. Research and development expenses were $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively, compared to $2.9 million and $10.2 million for the three and six months ended June 30, 2024, respectively. General and administrative expenses were $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and $23.1 million for the three and six months ended June 30, 2024, respectively. Restructuring and impairment charges were $0.5 million and $16.6 million for the three and six months ended June 30, 2025, respectively, compared to $0.5 million and $4.8 million for three and six months ended June 30, 2024, respectively. Net loss per share, basic and diluted were $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively, compared to $2.29 and $6.03 for the three and six months ended June 30, 2024, respectively. Non-GAAP net loss per share, basic and diluted, were $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively, compared to $1.57 and $3.95 for the three and six months ended June 30, 2024, respectively. Note Regarding Use of Non-GAAP Financial Measures In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil's operating results. In addition, these non-GAAP financial measures are among the indicators Instil's management uses for planning purposes and to measure Instil's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. About Instil Bio Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential of AXN-2510/IMM2510, clinical development of AXN-2510/IMM2510, including the initiation of clinical trials for AXN-2510/IMM2510 and the generation and presentation of clinical data for AXN-2510/IMM2510 and the timing thereof; research, development, regulatory and clinical plans for AXN-2510/IMM2510; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process and the sufficiency of Instil's cash resources; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts: Investor Relations:1-972-499-3350 investorrelations@ INSTIL BIO, FINANCIAL DATA (Unaudited; in thousands, except share and per share amounts) Selected Condensed Consolidated Balance Sheet Data June 30, 2025 December 31, 2024 Cash, cash equivalents, restricted cash, marketablesecurities and long-term investments $ 103,632 $ 115,145 Total assets $ 230,986 $ 263,567 Total liabilities $ 99,316 $ 94,131 Total stockholders' equity $ 131,670 $ 169,436 Condensed Consolidated Statements of Operations Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: In-process research and development $ 10,000 $ — $ 10,000 $ — Research and development 6,743 2,921 12,114 10,177 General and administrative 6,157 10,706 15,266 23,130 Restructuring and impairment charges 540 508 16,622 4,783 Total operating expenses 23,440 14,135 54,002 38,090 Loss from operations (23,440 ) (14,135 ) (54,002 ) (38,090 ) Interest income 1,044 1,919 2,219 3,981 Interest expense (1,582 ) (1,999 ) (2,680 ) (3,980 ) Other rental income 2,242 — 4,484 — Other income (expense), net 342 (702 ) 385 (1,130 ) Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Weighted-average shares used incomputing net loss per share, basic anddiluted 6,596,975 6,503,913 6,564,994 6,503,913 INSTIL BIO, of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Adjustments: Non-cash stock-based compensationexpense 1,824 4,173 5,319 8,688 Restructuring and impairmentcharges 540 508 16,622 4,783 Non-GAAP net loss $ (19,030 ) $ (10,236 ) $ (27,653 ) $ (25,748 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Adjustments: Non-cash stock-based compensationexpense per share 0.28 0.64 0.81 1.34 Restructuring and impairmentcharges per share 0.08 0.08 2.53 0.74 Non-GAAP net loss per share, basicand diluted* $ (2.88 ) $ (1.57 ) $ (4.21 ) $ (3.95 ) Weighted-average shares outstanding,basic and diluted 6,596,975 6,503,913 6,564,994 6,503,913 * Non-GAAP net loss per share, basic and diluted may not total due to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Integrated Dermatology Welcomes Mohs Surgeon Dr. Partik Singh to Dermatology Associates of Westlake Village
Integrated Dermatology Welcomes Mohs Surgeon Dr. Partik Singh to Dermatology Associates of Westlake Village

Associated Press

time7 minutes ago

  • Associated Press

Integrated Dermatology Welcomes Mohs Surgeon Dr. Partik Singh to Dermatology Associates of Westlake Village

BOCA RATON, Fla.--(BUSINESS WIRE)--Aug 13, 2025-- Integrated Dermatology, the country's largest independent dermatology provider, proudly announces that Partik Singh, M.D., has joined the clinical team at Dermatology Associates of Westlake Village. Fellowship-trained Mohs and reconstructive surgeon Dr. Singh, who specializes in skin cancer treatment, dermatologic surgery, cosmetic dermatology, and general medical dermatology, is now serving patients in Westlake Village and surrounding communities across Southern California. At Dermatology Associates of Westlake Village, Dr. Singh works alongside lead partner physician Simone Montgomery, M.D., M.P.H., and three additional dermatologists to provide comprehensive medical, surgical and cosmetic dermatology services. He specializes in skin cancer surgery, specifically Mohs micrographic surgery; reconstructive surgery for skin cancer; cosmetic dermatology; and general medical dermatology. His goal is to empower patients with high-quality treatment plans, education and compassionate support to ensure they feel confident and well informed. Dr. Singh earned a bachelor's degree in biochemistry from Case Western Reserve University before completing his M.D. and M.B.A. at Northwestern University's Feinberg School of Medicine and Kellogg School of Management. He served as chief resident during his dermatology residency at the University of Rochester Medical Center and completed a fellowship in micrographic surgery and dermatologic oncology at the University of California, San Francisco. 'Dr. Singh's expertise in skin cancer surgery and his compassionate approach to patient care make him a tremendous asset to our team,' said Dr. Montgomery. 'We're excited to welcome him and confident that his skills will greatly enhance the care we provide to our patients and the community.' Dermatology Associates of Westlake Village offers a full range of dermatology services to help patients maintain healthy skin. The practice provides general dermatology, dermatologic surgery, cosmetic treatments, microneedling and Ultherapy. To learn more about Singh and the practice, visit About Integrated Dermatology Headquartered in Boca Raton, Fla., Integrated Dermatology is one of the largest providers of dermatology services, empowering doctors nationwide through practice acquisitions, physician partnerships and new practice formations. Founded in 2004, the company operates in 28 states and enables its dermatologists to maintain their medical autonomy. With a doctor-driven philosophy and focus on high-quality patient care, Integrated Dermatology provides unparalleled back-office support, including accounting, payroll, human resources and much more. The company also offers career opportunities for dermatologists seeking to join an established practice. For additional information, visit View source version on CONTACT: MEDIA CONTACT: Jason Queen Chief of Staff [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA INDUSTRY KEYWORD: GENERAL HEALTH HEALTH OTHER HEALTH SOURCE: Integrated Dermatology Copyright Business Wire 2025. PUB: 08/13/2025 06:07 AM/DISC: 08/13/2025 06:07 AM

Welsh rugby's CEO diagnosed with cancer and stepping away from role
Welsh rugby's CEO diagnosed with cancer and stepping away from role

Yahoo

time35 minutes ago

  • Yahoo

Welsh rugby's CEO diagnosed with cancer and stepping away from role

CARDIFF, Wales (AP) — The top official in Welsh rugby is stepping away to undergo treatment after being diagnosed with cancer. Abi Tierney, chief executive of the Welsh Rugby Union, will leave her role temporarily on Aug. 22 'to focus fully on my health and recovery.' 'I am grateful for the support I have already received from my family, friends, and colleagues,' Tierney said, 'and I am confident in the team's ability to continue our work during my absence.' Tierney has just overseen the appointment of Steve Tandy as coach of the men's national team, which went on a record 18-match losing run before a win in Japan last month. ___ AP rugby:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store